as could we assure safety in large-scale manufacturing of nanoparticles for the biomedical use我们可以保证安全在大规模生产纳米颗粒的生物医学使用.pdfVIP

Journal of Biomaterials and Nanobiotechnology, 2011, 2, 601-613 601 doi:10.4236/jbnb.2011.225072 Published Online December 2011 (/journal/jbnb) As Could We Assure Safety in Large Scale Manufacturing of Nanoparticles for Biomedical Applications 1 1 2 Kirill Serguey Maksimov , Serguei Kirillovich Maksimov , Nikolay Dmitrievich Soukhov 1Laboratory of Electron Microscopy, National Research University of Electronic Technology, Moscow, Russia; 2Faculty of Physics, Lomonosov Moscow State University, Moscow, Russia. E-mail: maksimov_sk@comtv.ru Received September 11th, 2011; revised October 19th, 2011; accepted November 8th, 2011. ABSTRACT Nanoparticles provide great advantages but also great risks. Risks associating with nanoparticles are the problem of all technologies, but they increase in many times in nanotechnologies. Adequate methods of outgoing production inspec- tion are necessary to solve the problem of risks, and the inspection must be based on the safety standard. Existing safety standard results from a principle of “maximum permissible concentrations or MPC”. This principle is not applicable to nanoparticles, but a safety standard reflecting risks inherent in nanoparticles doesn’t exist. Essence of the risks is illus- trated by the example from pharmacology, since its safety assurance is conceptually based on MPC and it has already come against this problem. Possible formula of safety standard for nanoparticles is reflected in many publications, but conventional inspection methods cannot provide its realization, and this gap is an obstacle to assumption of similar formulas. Therefore the d evelopment of nanoparticle industry as a whole (also development of the pharmacology in particular ) is impossible without the creation of an